Eli Lilly and Company (NYSE:LLY) Shares Bought by One Wealth Management Investment & Advisory Services LLC

One Wealth Management Investment & Advisory Services LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 2.1% during the second quarter, Holdings Channel.com reports. The firm owned 817 shares of the company’s stock after purchasing an additional 17 shares during the period. One Wealth Management Investment & Advisory Services LLC’s holdings in Eli Lilly and Company were worth $740,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of LLY. Vanguard Group Inc. boosted its stake in Eli Lilly and Company by 1.6% during the first quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock worth $56,592,709,000 after buying an additional 1,133,810 shares during the period. Capital World Investors boosted its position in shares of Eli Lilly and Company by 0.3% during the 4th quarter. Capital World Investors now owns 26,949,773 shares of the company’s stock worth $15,709,466,000 after purchasing an additional 89,720 shares during the period. Norges Bank purchased a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $5,992,890,000. Capital Research Global Investors boosted its position in shares of Eli Lilly and Company by 6.0% during the first quarter. Capital Research Global Investors now owns 8,031,531 shares of the company’s stock worth $6,248,210,000 after buying an additional 453,939 shares during the period. Finally, Capital International Investors grew its stake in shares of Eli Lilly and Company by 5.1% in the first quarter. Capital International Investors now owns 6,972,393 shares of the company’s stock valued at $5,424,243,000 after buying an additional 335,560 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 75,510 shares of the firm’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $860.78, for a total transaction of $64,997,497.80. Following the transaction, the insider now owns 97,793,810 shares of the company’s stock, valued at $84,178,955,771.80. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Over the last quarter, insiders sold 737,410 shares of company stock worth $669,719,100. Company insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the subject of several recent research reports. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday. Deutsche Bank Aktiengesellschaft upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and lifted their target price for the company from $725.00 to $1,025.00 in a report on Monday, August 12th. Berenberg Bank upped their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Barclays boosted their price objective on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Finally, Argus raised their target price on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $961.76.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded down $10.04 during trading hours on Friday, reaching $902.71. The stock had a trading volume of 3,439,999 shares, compared to its average volume of 3,063,074. The firm has a 50-day moving average of $895.97 and a 200-day moving average of $827.49. The firm has a market cap of $857.94 billion, a price-to-earnings ratio of 132.95, a PEG ratio of 2.91 and a beta of 0.41. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. Equities research analysts predict that Eli Lilly and Company will post 16.51 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.58%. Eli Lilly and Company’s payout ratio is 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.